edical technology group T2S announced on November 10, in a release published by the AMMC, the construction in Fes of a plant producing radiopharmaceutical drugs, carried by its subsidiary Cyclopharma.
Work began on October 1, for an investment estimated at 60 million dirhams including taxes. Commissioning is scheduled for the second quarter of 2028, subject to regulatory approvals.
These drugs are used in nuclear medicine, notably in oncology, cardiology and neurology. Some have a very short radioactive life, and the new plant is meant to better cover the needs of the Fes-Meknes and Oriental regions.
The building, with two basement levels and four floors above, will house a bunker for a cyclotron producing radioisotopes, production and quality control laboratories, as well as storage and radioactive waste management areas.
As the program presented at its stock market listing in July planned, Cyclopharma will thus become a two-site manufacturer, Fes joining its plant in Bouskoura-Oulad Saleh, near Casablanca.
Photo: La Nouvelle Tribune.
